Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors

References

• ColemanRESkeletal complications of malignancyCancer199780Suppl 8158815949362426
   PubMed Web of Science ®Google Scholar
• ColemanREThe clinical course of bone metastases from breast cancerBr J Cancer198755161663814476
   PubMed Web of Science ®Google Scholar
• MercandanteSMalignant bone pain: pathophysiology and treatmentPain1997691–21189060007
   PubMed Web of Science ®Google Scholar
• LiptonAPamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastasesCancer20005881082109010699899
   PubMed Web of Science ®Google Scholar
• RosenLSLong-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumorsCancer2004100122613262115197804
   PubMed Web of Science ®Google Scholar
• SaadFClinical benefits of zoledronic acid for the prevention of skeletal complications in advanced prostate cancerClin Prostate Cancer200541313715992459
   PubMedGoogle Scholar
• HortobagyiGNBone metastases in breast cancer patientsSemin Oncol199118Suppl 511151925624
   PubMedGoogle Scholar
• KohnoNZoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trialJ Clin Oncol200523153314332115738536
   PubMed Web of Science ®Google Scholar
• RosenLSZoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least on osteolytic lesionCancer20041001364314692022
   PubMed Web of Science ®Google Scholar
• SaddFGleasonDMMurrayRA randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinomaJ Natl Cancer Inst200294191458146812359855
   PubMedGoogle Scholar
• RosenLSGordonDKaminskiMLong-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trialCancer20039881735174414534891
   PubMed Web of Science ®Google Scholar
• Zometa [package insert]East Hanover, NJNovartis Pharmaceuticals2001
   Google Scholar
• BekkerPJHollowayDLRasmussenASA single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal womenJ Bone Miner Res200520122275228216432953
   PubMed Web of Science ®Google Scholar
• CummingsSRSan MartinJMcClungMRDenosumab for prevention of fractures in postmenopausal women with osteoporosisN Engl J Med2009361875676519671655
   PubMed Web of Science ®Google Scholar
• BrownJPPrinceRLDealCComparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trialJ Bone Miner Res200924115316118767928
   PubMed Web of Science ®Google Scholar
• EastellRAromatase inhibitors and boneJ Steroid Biochem Mol Biol20071061–515716117643293
   PubMed Web of Science ®Google Scholar
• HillnerBEIngleJNChlebowskiRTAmerican Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancerJ Clin Oncol200321214042405712963702
   PubMed Web of Science ®Google Scholar
• NCCN Guidelines Version 12012Breast Cancer. 01/20/12National Comprehensive Cancer Network Inc Available from: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdfAccessed February 14, 2012
   Google Scholar
• EllisGKBoneHGChlebowskiRRandomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancerJ Clin Oncol200826304875488218725648
   PubMed Web of Science ®Google Scholar
• SmithMREgerdieBHernández TorizNDenosumab in men receiving androgen-deprivation therapy for prostate cancerN Engl J Med2009361874575519671656
   PubMed Web of Science ®Google Scholar
• Xgeva^® [package insert]Thousand Oaks, CAAmgen Inc2010
   Google Scholar
• FizaziKLiptonAMarietteXRandomized Phase II trial of denosumab in patients with one metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonatesJ Clin Oncol200927101564157119237632
   PubMed Web of Science ®Google Scholar
• LiptonAStegerCGFigueroaJRandomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastasesJ Clin Oncol200125284431443717785705
   PubMed Web of Science ®Google Scholar
• TabriziMATsengCMRoskosLEElimination mechanism of therapeutic monoclonal antibodiesDrug Discov Today2006111–2818816478695
   PubMed Web of Science ®Google Scholar
• KongYYYoshidaHSarosiIOPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesisNature199939767173153239950424
   PubMed Web of Science ®Google Scholar
• MillerPDWagmanRBPeacockMEffect of denosumab on bone mineral density and biochemical markers of bone turnover: six year results of a phase 2 clinical trialJ Clin Endocrinol Metab201196239440221159841
   PubMed Web of Science ®Google Scholar
• StopeckATLiptonABodyJJDenosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blinded studyJ Clin Oncol201028355132523921060033
   PubMed Web of Science ®Google Scholar
• StopeckAMartinMRitchieDEffect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phaseAbstract P6-14-01, presented at San Antonio Breast Cancer SymposiumDecember 8–12, 2010San Antonio, TX
   Google Scholar
• StopeckALiptonACampbell-BairdCAcute-phase reaction following treatment with zoledronic acid or denosumab: results from a randomized, controlled phase 3 Study in patients with breast cancer and bone metastasesAbstract P6-14-09, presented at San Antonio Breast Cancer SymposiumDecember 8–12, 2010San Antonio, TX
   Google Scholar
• FallowfieldLPatrickDBodyJEffects of denosumab versus zoledronic acid (ZA) on health-related quality of life (HRQL) in metastatic breast cancer: Results from a randomized phase III trialAbstract number 1025, presented at the ASCO annual meetingJune 4–8, 2010Chicago, IL
   Google Scholar
• Van PoznakCHTeminSYeeGCAmerican Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancerJ Clin Oncol201129161221122721343561
   PubMed Web of Science ®Google Scholar
• FizaziKCarducciMSmithMDenosumab versus zoledronic acid for the treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind studyLancet2011377976881382221353695
   PubMed Web of Science ®Google Scholar
• BrownJECookRJMajorPBone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumorsJ Natl Cancer Inst2005971596915632381
   PubMed Web of Science ®Google Scholar
• NCCN Guidelines Version 12012Prostate Cancer. 02/22/12National Comprehensive Cancer Network Inc Available from: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdfAccessed February 14, 2012
   Google Scholar
• HenryDHCostaLGoldwasserFRandomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myelomaJ Clin Oncol20012991125113221343556
   PubMed Web of Science ®Google Scholar
• RichardsonGECiuleanuTECostaLDenosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: A number needed to treat (NNT) analysisAbstract number 9115, presented at the ASCO annual meetingJune 3–7, 2011Chicago, IL
   Google Scholar
• von MoosRPatrickDFallowfieldLEffects of denosumab versus zoledronic acid on pain in patients with advanced cancer (excluding breast and prostate) or multiple myeloma: Results from a randomized phase III clinical trialAbstract number 9043, presented at the ASCO annual meetingJune 4–8, 2010Chicago, IL
   Google Scholar
• LiptonAFizaziKStopeckAPrevention of skeletal-related events with denosumab or zoledronic acid: combined analysis from 3 registrational trialsAbstract number 3061, presented at the European Multidisciplinary Cancer CongressSeptember 23–27, 2011Stockholm, Sweden
   Google Scholar
• DielIJBodyJJStopeckAEffect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with bone metastasisAbstract number 3051, presented at the European Multidisciplinary Cancer CongressSeptember 23–27, 2011Stockholm, Sweden
   Google Scholar
• SaadFBrownJEVan PoznakCIncidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active controlled phase III trials in cancer patients with bone metastasesAnn Oncol2011Epub Oct10
   Google Scholar
• StopeckATLiptonAMartinMDenosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab: results from the 2-year open-label extension treatment phase of a pivotal phase 3 studyAbstract P3-16-07, presented at the San Antonio Breast Cancer SymposiumDecember 6–10, 2011San Antonio, TX
   Google Scholar
• KendlerDLRouxCBenhamouCLEffects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapyJ Bone Miner Res2010251728119594293
   PubMed Web of Science ®Google Scholar
• GnantMMineritschBSchippingerWEndocrine therapy plus zoledronic acid in premenopausal breast cancerN Engl J Med20093602267969119213681
   PubMed Web of Science ®Google Scholar
• ColemanREMarshallHCameronDBreast-cancer adjuvant therapy with zoledronic acidN Engl J Med20113651513971405
   Web of Science ®Google Scholar
• JonesDHNakashimaTSanchezOHRegulation of cancer cell migration and bone metastasis by RANKLNature2006440708469269616572175
   PubMed Web of Science ®Google Scholar
• Study of denosumab as adjuvant treatment for women with high risk early breast cancer receiving neoadjuvant or adjuvant therapy (D-CARE) Available from: http://clinicaltrials.gov/ct2/show/NCT01077154Accessed December 15, 2011
   Google Scholar
• RodmanGDMechanisms of bone metastasisN Engl J Med2004350161655166415084698
   PubMed Web of Science ®Google Scholar
• SmithMSaadFColemanRDenosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomized, placebo-controlled trialLancet20123799810394622093187
   PubMed Web of Science ®Google Scholar